Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

98.07 +1.83 (+1.90%)
Streaming Delayed Price Updated: 12:55 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Nasdaq Flashes A Stealth Buy Signal: What’s Next?
The Nasdaq is now trading above its 20-day exponential moving average. 
Via Talk Markets
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Small Cap Biotech Stocks Are Trending Well
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
CNBC's Final Trades: Biotech, CVS Health, Walt Disney And This Stock That Could Benefit From Taiwan Semiconductor's Earnings Release
On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management chose SPDR S&P Biotech ETF (NYSE: XBI). 
Via Benzinga
CNBC Fast Money Favorites: AMD, CVS, And One Of The Worst Performers In The S&P 500 Today
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. The... 
Via Benzinga
Time For A Pause Or Mild Pullback?
The stock market has had a nice little rally over the past week. It still needs to clear some upside to see that defined higher highs and higher lows, but let’s not be greedy here. 
Via Talk Markets
5 ETFs Riding High On The Biotech Comeback
The high-growth biotech segment has borne the maximum brunt of the broader market sell-off. 
Via Talk Markets
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
3 Biotech Stocks to Sell Now
These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
3 Stocks to Sell Now
Equities suffer from the highest inflation readings of a generation. Here's a trio of S&P 500 stocks to sell before things get worse. 
Via InvestorPlace
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
U.S. Weekly FundFlows Insight Report: Sector-Energy Funds Report $1.3 Billion in Outflows, Fourth Largest on Record
During fund-flows week ended June 22, 2022, investors were overall net sellers of fund assets (including both conventional funds and ETFs) for the second straight week, withdrawing a net $20.1... 
Via Talk Markets
3 Beaten-Down ETFs to Buy Before They Rebound
The charts are improving for these fallen angels, and that makes them all top ETFs to buy for the back half of the year. 
Via InvestorPlace
“Should’ve Been Me” Stock Market (And Sentiment Results)
In this week’s AAII Sentiment Survey result, bullish percent ticked down to 18.2% this week from 19.4% last week. 
Via Talk Markets
Option Bears Reloading as Bulls Feeling Spry
As the bulls have their moment, the bears are adding bearish options positions and rolling up into the strength. 
Via Talk Markets
Stock Drop On June 16, But A Rally May Be Coming After Options Expiration
Another miserable day for stocks, with the S&P 500 dropping 3.25% 
Via Talk Markets
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Crispr and Vertex tested their gene-edited drug in two blood diseases. 
Via Investor's Business Daily
“Chip Shot” Stock Market (And Sentiment Results)
Chips are the key to the economy/inflation moving forward. They are also the key to one of our major new positions in an auto-supplier 
Via Talk Markets
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Again, Buy ‘Em
Today we discuss again why it’s time to start adding back risk. We cover the major breadth thrusts that fired, some great monthly charts, and more. 
Via Talk Markets
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data... 
Via Benzinga
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
Via Benzinga
This Biotech Looks Good With Increased M&A activity
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for... 
Via Talk Markets
The “Mystery Liquidator Revealed” Stock Market (And Sentiment Results)
In this week’s AAII Sentiment Survey result, Bullish Percent ticked up a hair to 26% this week from 24.3% last week. Bearish Percent rose to 50.4% from 49%. 
Via Talk Markets
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
When Will The Stock Market Stop Falling?
Stocks have fallen dramatically just this past week, is a bottom near? 
Via Talk Markets
Stocks Tank On May 11 With No Bottom In Sight
Despite the sharp decline, the VIX finished down on the day at 32.5. It tells us there was “real” selling in the market today. 
Via Talk Markets
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
Should Biotech Be On The Critical List?
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.